<SEC-DOCUMENT>0001193125-24-253174.txt : 20241107
<SEC-HEADER>0001193125-24-253174.hdr.sgml : 20241107
<ACCEPTANCE-DATETIME>20241107162954
ACCESSION NUMBER:		0001193125-24-253174
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20241107
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241107
DATE AS OF CHANGE:		20241107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcellx, Inc.
		CENTRAL INDEX KEY:			0001786205
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				472855917
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41259
		FILM NUMBER:		241436317

	BUSINESS ADDRESS:	
		STREET 1:		800 BRIDGE PARKWAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		240-327-0603

	MAIL ADDRESS:	
		STREET 1:		800 BRIDGE PARKWAY
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d862473d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:aclx="http://arcellx.com/20241107" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-238">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-11-07_to_2024-11-07">0001786205</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="aclx-20241107.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-11-07_to_2024-11-07"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001786205</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-11-07</xbrli:startDate> <xbrli:endDate>2024-11-07</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-249">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-11-07_to_2024-11-07" format="ixt:datemonthdayyearen" id="ixv-250">November 7, 2024</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-251">Arcellx, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-11-07_to_2024-11-07" format="ixt-sec:stateprovnameen" id="ixv-252">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-253">001-41259</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-254">47-2855917</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or Other Jurisdiction<br/>of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br/>File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:99%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-255">800 Bridge Parkway</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-256">Redwood City</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-257">CA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-258">94065</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices, including zip code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-259">(240)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-260">327-0630</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-11-07_to_2024-11-07" format="ixt-sec:boolballotbox" id="ixv-261">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-11-07_to_2024-11-07" format="ixt-sec:boolballotbox" id="ixv-262">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-11-07_to_2024-11-07" format="ixt-sec:boolballotbox" id="ixv-263">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-11-07_to_2024-11-07" format="ixt-sec:boolballotbox" id="ixv-264">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-265">Common Stock, $0.001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-266">ACLX</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-11-07_to_2024-11-07" format="ixt-sec:exchnameen" id="ixv-267">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#8201;240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-11-07_to_2024-11-07" format="ixt-sec:boolballotbox" id="ixv-268">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;2.02 Results of Operations and Financial Condition. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;7, 2024, Arcellx, Inc. (the &#8220;Company&#8221;) issued a press release announcing the Company&#8217;s financial results for the fiscal quarter ended September&#160;30, 2024. A copy of the Company&#8217;s press release is attached hereto as Exhibit 99.1. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information furnished pursuant to Item 2.02 on this Form <span style="white-space:nowrap">8-K,</span> including Exhibit 99.1 attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d862473dex991.htm">Press Release dated November&#160;7, 2024 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL Document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:47%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Arcellx, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: November&#160;7, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rami Elghandour</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Rami Elghandour</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d862473dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g862473g1108005806784.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151; Recently released ASH abstracts for the company&#146;s Phase 1 and <FONT STYLE="white-space:nowrap">iMMagine-1</FONT> studies
investigating <FONT STYLE="white-space:nowrap">anito-cel</FONT> in relapsed or refractory multiple myeloma patients continue to demonstrate durability and a manageable safety profile &#151; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151; <FONT STYLE="white-space:nowrap">30.2-month</FONT> median progression-free survival with a median
<FONT STYLE="white-space:nowrap">follow-up</FONT> of 38.1 months in the Phase 1 study of <FONT STYLE="white-space:nowrap">anito-cel;</FONT> median overall survival not reached &#151; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151; Preliminary results from 58 patients enrolled in the Phase 2 pivotal <FONT STYLE="white-space:nowrap">iMMagine-1</FONT> study
demonstrated 95% ORR and 62% CR/sCR at a median <FONT STYLE="white-space:nowrap">follow-up</FONT> of 10.3 months; additional patients with a more recent data cut will be presented during an oral presentation &#151; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151; No delayed neurotoxicities have been observed to date with <FONT STYLE="white-space:nowrap">anito-cel,</FONT> including no
parkinsonism, no cranial nerve palsies, and no Guillain-Barr&eacute; syndrome across the Phase 1 and <FONT STYLE="white-space:nowrap">iMMagine-1</FONT> studies in the more than 140 patients dosed &#151; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>&#151; First patients dosed in <FONT STYLE="white-space:nowrap">iMMagine-3</FONT> study, manufactured by Kite; turnaround time in line with
Kite&#146;s commercial products &#151; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>REDWOOD CITY, Calif., </B>November 7, 2024 &#150; Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company
reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the third quarter ended September&nbsp;30, 2024, and provided recent business
highlights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We believe the data from the recently published ASH abstracts continues to differentiate
<FONT STYLE="white-space:nowrap">anito-cel&#146;s</FONT> clinical profile as a potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment option for multiple myeloma patients,&#148; said Rami
Elghandour, Arcellx&#146;s Chairman and Chief Executive Officer. &#147;The <FONT STYLE="white-space:nowrap">30.2-month</FONT> median progression-free survival demonstrated in our Phase 1 study in a challenging patient cohort coupled with the
promising results from our <FONT STYLE="white-space:nowrap">iMMagine-1</FONT> Phase 2 registrational study highlight the potential impact we could have for patients. That impact is further enhanced by the high tolerability demonstrated through both
the Phase 1 and <FONT STYLE="white-space:nowrap">iMMagine-1</FONT> studies to date, where notably, no delayed or <FONT STYLE="white-space:nowrap">non-ICANS</FONT> neurotoxicities were observed in the over 140 patients treated to date. Patients and
clinicians evaluate cell therapies on their safety, efficacy, delivery reliability, service, and accessibility. We believe we&#146;re well positioned to deliver on these important factors in a differentiated way that best serves the multiple myeloma
community. Our partnership with Kite allows us to leverage their established global commercial capabilities, positive brand recognition with physicians, and industry-leading manufacturing reliability and turnaround times which we believe contributes
to our competitive advantage. It&#146;s an exciting time at Arcellx! We are preparing for the commercial launch of <FONT STYLE="white-space:nowrap">anito-cel</FONT> as there remains an unmet need for a therapy that physicians can use across a broad
patient population.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Business Progress </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Announced presentations at the 66<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> American Society for Hematology Annual Meeting and Exposition: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Preliminary
Results From the <FONT STYLE="white-space:nowrap">iMMagine-1</FONT> Trial (abstract #1031) </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As detailed in the abstract (#1031) as of June&nbsp;1, 2024, 58 patients had received <FONT
STYLE="white-space:nowrap">anito-cel</FONT> infusion with &#8805;2 months of <FONT STYLE="white-space:nowrap">follow-up</FONT> after infusion, with a median <FONT STYLE="white-space:nowrap">follow-up</FONT> of 10.3 months (range, <FONT
STYLE="white-space:nowrap">2.0-17.8).</FONT> The median age was 66 years (range, <FONT STYLE="white-space:nowrap">38-77).</FONT> Patients had received a median of four prior lines of treatment (range, <FONT STYLE="white-space:nowrap">3-8)</FONT>
with 26 patients (45%) having received only three prior lines of treatment. Forty patients (69%) were triple-class refractory and 20 (34%) were penta-class refractory. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investigator-assessed overall response rate (ORR) per International Myeloma Working Group (IMWG) criteria was 95% (55/58) with a complete response/stringent
complete response (CR/sCR) rate of 62% (36/58). Of those evaluable for minimal residual disease (MRD) testing (n=39), 36 (92%) achieved MRD negativity at least to the level of 10<SUP STYLE="font-size:75%; vertical-align:top">-5</SUP>. The
Kaplan&#150;Meier-estimated <FONT STYLE="white-space:nowrap">6-month</FONT> progression-free survival (PFS) and overall survival (OS) rates (95% CI) were 90% <FONT STYLE="white-space:nowrap">(77-96)</FONT> and 95%
<FONT STYLE="white-space:nowrap">(85-98),</FONT> respectively. Median (mPFS) and median OS have not yet been reached. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No delayed neurotoxicities,
including no parkinsonism, no cranial nerve palsies, and no Guillain-Barr&eacute; syndrome have been observed to date.<I> </I><FONT STYLE="white-space:nowrap">Forty-six</FONT> patients (79%) had either no cytokine release syndrome (CRS) (n=9, 16%)
or Grade (Gr) 1 CRS (n=37, 64%). <FONT STYLE="white-space:nowrap">Thirty-one</FONT> patients (53%) had no fever or CRS in the first four days of <FONT STYLE="white-space:nowrap">anito-cel.</FONT> Any Grade CRS was observed in 49 patients (84%; Gr3/4
0%). Any Grade ICANS was observed in 5 patients (9%; Gr3 2%), with all cases resolved without sequelae. Three deaths occurred due to adverse events (AEs) (both related and unrelated; retroperitoneal hemorrhage, CRS, and fungal infection). No
additional treatment or therapy-related deaths or Grade &#8805;3 CRS or ICANs events have occurred to date. Cytopenias were the most common Grade &#8805;3 treatment-emergent AEs; 36 patients (62%) had Grade &#8805;3 neutropenia, 15 (26%) had Grade
&#8805;3 thrombocytopenia, and 15 (26%) had Grade &#8805;3 anemia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conclusions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preliminary results from the first 58 patients in the Phase 2 <FONT STYLE="white-space:nowrap">iMMagine-1</FONT> study demonstrate deep and durable responses
and manageable safety in a high-risk fourth line or higher (4L+) RRMM population including triple- and penta-class refractory disease. Notably, no delayed neurotoxicities, including no cranial nerve palsies, Guillain-Barr&eacute; syndrome, or
Parkinsonian-like symptoms have been observed with <FONT STYLE="white-space:nowrap">anito-cel</FONT> to date. Updated Phase 2 data with a more recent data cut will be presented at the oral presentation during ASH. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Presentation details: </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Speaker</B>: Ciara
Freeman, M.D., Ph.D., H. Lee Moffitt Cancer Center </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session Name</B>: 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against
Myeloma </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session Date</B>: Monday, December&nbsp;9, 2024 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session Time</B>: 4:30 p.m. - 6:00 p.m. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presentation
Time</B>: 5:30 p.m. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Location</B>: Marriott Marquis San Diego Marina, Pacific Ballroom Salons <FONT STYLE="white-space:nowrap">24-26</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Publication Number</B>: 1031 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Submission ID</B>: 198499
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (abstract #4825)
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Phase 1 study, 40 patients were enrolled and 38 patients received <FONT STYLE="white-space:nowrap">anito-cel.</FONT> All 38 patients
demonstrated investigator-assessed clinical response per 2016 IMWG criteria, (ORR, 100%) with 30 CR/sCR (&#8805;CR rate, 79%), 5 very good partial response (&#8805;VGPR rate, 92%), and 3 partial response (PR). Of those evaluable for MRD testing
(n=28), 25 (89%) achieved MRD negativity at 10<SUP STYLE="font-size:75%; vertical-align:top">-5</SUP>. With a median <FONT STYLE="white-space:nowrap">follow-up</FONT> of 38.1 months, median OS was not reached and median PFS was 30.2 months. The
safety profile was manageable with no delayed neurotoxicities observed to date, including no parkinsonism, no cranial nerve palsies, and no Guillain-Barr&eacute; syndrome. Further investigations of <FONT STYLE="white-space:nowrap">anito-cel</FONT>
are ongoing in 4L+ RRMM <FONT STYLE="white-space:nowrap">(iMMagine-1,</FONT> NCT05396885) and in earlier lines <FONT STYLE="white-space:nowrap">(iMMagine-3,</FONT> NCT06413498). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Presentation details: </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Speaker</B>: Michael R. Bishop, M.D., The University of Chicago </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session Name</B>: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session Date</B>: Monday, December&nbsp;9, 2024 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presentation Time</B>: 6:00 p.m. - 8:00 p.m. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Location</B>:
San Diego Convention Center, Halls <FONT STYLE="white-space:nowrap">G-H</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Publication Number</B>: 4825 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Submission ID</B>: 201080 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Health Related Quality of Life
(HRQoL) in Relapsed/Refractory Multiple Myeloma (RRMM): A Systematic Literature Review (SLR) and Meta-Analysis (abstract #4721) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Quantifying <FONT
STYLE="white-space:nowrap">pre-treatment</FONT> HRQoL burden&nbsp;is important as&nbsp;a reference for contextualizing baseline patient burden as emerging therapies for RRMM continue to evolve.&nbsp;This SLR synthesized studies that reported data
for key multiple myeloma HRQoL instruments. It found that patients with RRMM had clinically meaningful impairments from population norms in important domains, such as Global Health Status and cognitive, physical, and emotional functioning. The SLR
also found that <FONT STYLE="white-space:nowrap">pre-treatment</FONT> HRQoL worsened with increasing lines of therapy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Presentation details:
</U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Speaker</B>: Rahul Banerjee, M.D., Fred Hutchinson Cancer Center </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session Name</B>: 653. Multiple Myeloma: Clinical and Epidemiological: Poster III </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session Date</B>: Monday, December&nbsp;9, 2024 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presentation Time</B>: 6:00 p.m. - 8:00 p.m. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Location</B>:
San Diego Convention Center, Halls <FONT STYLE="white-space:nowrap">G-H</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Treatment Patterns and Outcomes in Triple-Class Exposed Patients with
Relapsed and Refractory Multiple Myeloma: Findings from the Flatiron Database (abstract #6962) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to understand the contemporary unmet need in
the rapidly evolving treatment landscape for patients with triple-class exposed RRMM&#151;those exposed to immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies&#151;in the 4L+ setting, a retrospective cohort study using
the Flatiron Health electronic health record (HER) was conducted (sample size=594). This study found no clear standard of care in the 4L+ setting, and suboptimal health outcomes under the current treatment landscape (ORR=34%, PFS=4.1 months, and
OS=15.4 months), emphasizing an urgent need for more effective and durable therapies for patients in this setting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This abstract will be published in a
supplemental issue of <I>Blood</I> in November 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">First patients dosed in <FONT STYLE="white-space:nowrap">iMMagine-3,</FONT> a global randomized
Phase 3 study, assessing <FONT STYLE="white-space:nowrap">anito-cel</FONT> in patients previously treated with both an immunomodulatory (IMiD) drug and an anti-CD38 monoclonal antibody. Kite is manufacturing for this study. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Third Quarter 2024 Financial Highlights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash, cash
equivalents, and marketable securities: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2024, Arcellx had cash, cash equivalents, and marketable securities of
$676.7&nbsp;million. Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2027. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration
revenue: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration revenue were $26.0&nbsp;million and $15.0&nbsp;million for the quarters ended September&nbsp;30, 2024 and 2023, respectively,
an increase of $11.0&nbsp;million. This increase was primarily driven by the December 2023 expansion to the license and collaboration agreement with Kite Pharma, Inc. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>R&amp;D expenses: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses were $39.2&nbsp;million and $43.8&nbsp;million for the quarters ended September&nbsp;30, 2024 and 2023, respectively, a
decrease of $4.6&nbsp;million. This decrease was primarily driven by an expense in 2023 associated with our Lonza manufacturing services agreement. The decrease was partially offset by increased costs relating to other preclinical pipeline programs
and increased personnel costs, which include <FONT STYLE="white-space:nowrap">non-cash</FONT> stock-based compensation expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>G&amp;A expenses:
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $20.5&nbsp;million and $16.0&nbsp;million for the quarters ended September&nbsp;30, 2024 and 2023,
respectively, an increase of $4.5&nbsp;million. This increase was primarily driven by increased personnel costs, which include <FONT STYLE="white-space:nowrap">non-cash</FONT> stock-based compensation expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Net losses: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net losses were $25.9&nbsp;million and
$39.3&nbsp;million for the quarters ended September&nbsp;30, 2024 and 2023, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Upcoming Webcast Event: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arcellx will host a live webcast event with an expert panel of clinicians on Monday, December&nbsp;9, 2024, at 8:30 p.m. PT to discuss clinical results from
its Phase 1 and <FONT STYLE="white-space:nowrap">iMMagine-1</FONT> trials. The event will be accessible from Arcellx&#146;s website at&nbsp;www.arcellx.com in the Investors section. A webcast replay will be archived and available for 30 days
following the event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Arcellx and Kite Collaboration </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arcellx and Kite, a Gilead Company, formed a global strategic collaboration and license agreement to <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT
STYLE="white-space:nowrap">co-commercialize</FONT> <FONT STYLE="white-space:nowrap">anito-cel</FONT> for patients with relapsed or refractory multiple myeloma, RRMM. <FONT STYLE="white-space:nowrap">Anito-cel</FONT> is currently being developed in a
Phase 2 registrational pivotal study and a Phase 3 randomized controlled study for RRMM. Kite and Arcellx will jointly commercialize the <FONT STYLE="white-space:nowrap">anito-cel</FONT> asset in the United States, and Kite will commercialize the
product outside the United States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Arcellx, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other
incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx&#146;s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. For more
information on Arcellx, please visit www.arcellx.com . Follow Arcellx on X @arcellx and LinkedIn. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
<FONT STYLE="white-space:nowrap">iMMagine-3,</FONT> A Global Randomized Controlled Phase 3 Study </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">iMMagine-3</FONT> is
a Phase 3, global randomized controlled study designed to compare the efficacy and safety of anitocabtagene autoleucel <FONT STYLE="white-space:nowrap">(anito-cel)</FONT> with SOC in patients with relapsed and/or refractory multiple myeloma (RRMM)
who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody. <FONT STYLE="white-space:nowrap">iMMagine-3</FONT> will enroll approximately 450 adult patients. Prior to
randomization, investigator&#146;s choice of SOC regimens include: pomalidomide, bortezomib, and dexamethasone (PVd); daratumumab, pomalidomide, and dexamethasone (DPd); carfilzomib, daratumumab and dexamethasone (KDd); or carfilzomib and
dexamethasone (Kd). Patients in the <FONT STYLE="white-space:nowrap">anito-cel</FONT> arm will undergo leukapheresis and optional bridging therapy (with the SOC regimen selected by the investigator prior to randomization) followed by lymphodepleting
chemotherapy (fludarabine 30 mg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>/d and cyclophosphamide 300 mg/m<SUP STYLE="font-size:75%; vertical-align:top">2</SUP>/d for 3 days) and one infusion of
<FONT STYLE="white-space:nowrap">anito-cel</FONT> (115&times;10<SUP STYLE="font-size:75%; vertical-align:top">6</SUP> CAR+ T cells) on Day 1. The primary endpoint is progression free survival (PFS) per blinded independent review according to the
2016 IMWG uniform response criteria for MM with the hypothesis that <FONT STYLE="white-space:nowrap">anito-cel</FONT> will prolong PFS compared to SOC. Key secondary endpoints include complete response rate (CR/sCR), minimal residual disease
negativity, overall survival, and safety. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E
of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements, including, without limitation, statements regarding: the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> potential of <FONT STYLE="white-space:nowrap">anito-cel</FONT> for patients suffering from multiple myeloma; the potential impact of <FONT STYLE="white-space:nowrap">anito-cel</FONT> on rrMM
patients; <FONT STYLE="white-space:nowrap">anito-cel</FONT> tolerability and toxicity trends; Arcellx&#146;s competitive positioning; Arcellx&#146;s plans for the research, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical
development of its product candidates; the anticipated timing for the presentation of updated Phase 1 data and <FONT STYLE="white-space:nowrap">iMMagine-1</FONT> preliminary data; Arcellx&#146;s partnership with Kite; the potential commercial launch
of <FONT STYLE="white-space:nowrap">anito-cel,</FONT> subject to FDA approval; Arcellx&#146;s ability to deliver cell therapies that will meet the key expectations of patients and clinicians and serve the multiple myeloma community; and the
sufficiency of cash, cash equivalents and marketable securities and its ability to fund operations into 2027. The forward-looking statements contained herein are based upon Arcellx&#146;s current expectations and involve assumptions that may never
materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including risks that may be found in the section entitled Part II, Item 1A (Risk
Factors) in the Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2024, filed with the Securities and Exchange Commission (SEC) on or about the date hereof, and the other documents that
Arcellx may file from time to time with the SEC. These forward-looking statements are made as of the date of this press release, and Arcellx assumes no obligation to update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="8" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>ARCELLX, INC.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>SELECTED CONSOLIDATED BALANCE SHEET DATA</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">676,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">729,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">764,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">825,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">281,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">339,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">483,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">485,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="16" ALIGN="center"><B>ARCELLX, INC.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="16" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="16" ALIGN="center"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 26,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 14,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 92,670</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 47,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(33,616</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44,862</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(84,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(104,879</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39,342</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(59,703</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(564</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,867</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39,336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(60,267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90,534</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive loss:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain (loss) on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(23,176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(39,394</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(58,915</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90,378</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,821,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48,348,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53,367,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,777,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Myesha Lacy </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arcellx, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ir@arcellx.com </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">510-418-2412</FONT></FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Andrea Cohen </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sam Brown Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>andreacohen@sambrown.com </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">917-209-7163</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>###</B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>aclx-20241107.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241008.3 -->
<!-- Creation date: 11/8/2024 2:21:58 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:aclx="http://arcellx.com/20241107"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://arcellx.com/20241107"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="aclx-20241107_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="aclx-20241107_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>aclx-20241107_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241008.3 -->
<!-- Creation date: 11/8/2024 2:21:58 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>aclx-20241107_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241008.3 -->
<!-- Creation date: 11/8/2024 2:21:59 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="aclx-20241107.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g862473g1108005806784.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g862473g1108005806784.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !B 4\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YKQEX
MG?PW8PFWCCDNYWPBR [0H^\>.O4#&1U]JXD_%'7/^?73_P#OV_\ \75/QWJC
M:EXEFC63=!:_N8P,@ C[W![YR,CK@5Q=SJ=G:RF*>4HX&<%&_P *^FP> HJC
M%U(W;U.W#J#5FKGHMI\2?$%[>PVL-EI[23.$5=CC))QU+UZM7A?P_P!:T*WU
MI]1O-1\I;="$41.2S,".RGC&>XYQ7K>F>*]#UB[^RV-^LL^TL$*,A('7&X#/
MX5Y^98=1FO94[12U:3L5BZ3T<(62ZV-FBBBO). **** "BBB@ HHHH ****
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M7"?M!?\ ()T3_KO)_P"@BBFHNJDM@*,4GQRFB26,Y1U#*<67(/2G_P#%]?\
M/V&O2M.\8^&$TRT1_$FD*RPH"#?1 @[1_M59_P"$S\+?]#+HW_@?%_\ %57M
M)?R+[AG/_#[_ (3_ .TWW_":?ZK8GV;_ %'WLG=_JO;'6LCXB>+]=T+Q[X?T
MS3;[R+.[\OSX_)1M^9=IY921QZ&O2[*_L]2MEN;"[@NK=B0)8) ZDCKR.*\8
M^+?_ "5+PI_VQ_\ 1U*G:=35 >WT445SB,_7KF:R\.ZG=6[[)X+262-L [65
M"0<'CJ*XSX0^)M8\4>';Z[UF[^TSQ79C1O*1,+L4XPH ZDUUOBC_ )%'6O\
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M)_UWD_\ 0154DE62B!:L_@3X8N+&WG>_U@-)&KD":+&2,_\ /.I_^%!^%O\
MG_UG_O\ 1?\ QNN>M?V@/LUI#!_PC.[RHU3=]OQG Q_SSJ7_ (:&_P"I7_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
910 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45423087991664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 07, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001786205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  07,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Arcellx, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2855917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">800 Bridge Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(240)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">327-0630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACLX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( +J#9UGAU.W![P   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( +J#9UF97)PC$ 8  )PG   3
M      "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ NH-G
M6;C;X"M-!   C!   !@              ("!#@@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( +J#9UF?H!OPL0(  .(,   -
M      "  9$,  !X;"]S='EL97,N>&UL4$L! A0#%     @ NH-G69>*NQS
M    $P(   L              ( !;0\  %]R96QS+RYR96QS4$L! A0#%
M  @ NH-G61PX9>H_ 0  / (   \              ( !5A   'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( +J#9UDD'INBK0   /@!   :
M  "  <(1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M +J#9UEED'F2&0$  ,\#   3              "  :<2  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     )  D /@(  /$3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d862473d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aclx-20241107.xsd</File>
    <File>aclx-20241107_lab.xml</File>
    <File>aclx-20241107_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d862473d8k.htm">d862473d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d862473d8k.htm": {
   "nsprefix": "aclx",
   "nsuri": "http://arcellx.com/20241107",
   "dts": {
    "schema": {
     "local": [
      "aclx-20241107.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "aclx-20241107_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aclx-20241107_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d862473d8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-11-07_to_2024-11-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d862473d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-11-07_to_2024-11-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d862473d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://arcellx.com//20241107/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-24-253174-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-253174-xbrl.zip
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MHA!DE2 OA?097XLV#!_RV7HI[[A26_KW3N2[:/;;%]2>_P!02P,$%     @
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M)*4&6B2.HXO(=B2-5B-NG5^2SCVYR:,(,F09;$OE;*789&K(3\G/)!==2R&
M<UB16R:H2!CE9. <_T)Z(JF1#N>D;V4:;6I0SY#6-E$Y$_^T[-/(FB?OWQ%\
M8!V%SEO;@:W&IAC+D>(UJ2;HMMZ,G"C8UBSW1(MF+HDO+R^C_&BQOV9EO7&
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MUO=5I^D4<;58C44A4ZY\W$<X*\VW(L.V3'*(A7B0@!P[!=PS3;14;4!+!/_
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M2*=B>BH1/2]/PX4]H/[5Y(#F,Z U_/"?P/!8#_R"$T.,;+P"E@A6"!\80V/
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M(CAFA \#F>IIN-2.C.$FXIZ6[4XH?!NS3[<I"TQC7C 8(S/.9,J=$MX>J,)
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MT;"FA@DT]2A/\.965C/Q!H'GS>0514GCZ12BWY\L^^#3GK0T'>%8I&,>5C[
MI" ,HLT5$0$&>%1AP)?#N+^_SW%Y2P[F*PR<R/-S6.[ DP<CP!F(F.<*Q^33
MN$>P]/)T(RK .VZ844H2L 7/J^#F#B;^J#TD2?%6A+#9QS,FL1^C2X YB\.W
M*9$A"1A%.S.PS (00[6+-.38A Z)JDB#3%H;&8-YR QM1( Z@L\@=T\*TL#.
M*CB6/,RVPLXC/!C75X A1T'HM>,<BZ'.%2LK:A3^7.&@57,AM.*%(3TP:GV!
M4JBX$(6O'J@:$Y;)DT%'6:XQC/G$<2!9Y4*F,H;A25=1*\MYP(,S*NG?MD'$
MS/!TM</X2PI6($)4Z_8K_(KFP$=?78L%GGI=Z(UJ[V"\%:.@GJ&+Q3:VOTHC
MMV]KBU+UB&'.2&5G/<S075YEC#U89 R@$E4]$L*5F7@_45B,#EO.51:+0S*J
MP(J*Q\S5SI'9@$)M]V)?]Q@<=S AT:5($F92#M _2(AF:"+"C!##4P?OD# V
M#B8H>C1&M7KFAA]M[&/WF(GI:G/Q;14<PFM4& 560&RNZ,0Y_8@C1UTHM1W\
M%\V3(\]IWAE@P]B\Z<(&T,I$/((G_\G^SA.:]\*PO@N]8VU/JE<X);PDV-P,
MTPRZL9)IQ4HF5$$RJWP;@='U2Q<:Z'*&E&J+P?-%I:D+SQBI.DRTTM1AR+#P
MD]S D1F^(,)\-I.>QYGT3V>G1DHT.M1-2[!WW9J)P\^:)Y5T_UCQ7YF"E$[=
MCVUY#"U1<D'(6-BRH@M2>R33C9<%^2FZGS$ITK]:D/\9TT:&0B;F,^Z >?A!
MY_1AI98K>5 &,.)$4;0;&HAO@]^I)I;6K#:39Q]5H1S; %HHC@U\1DL+N,4+
M7<<#Y@ '30-;T4%3]#$WZ+_PI:^I,-(//A&@7SQD9>;F3WW_$, EYG9-0#7U
MM;GGESQS<H//#+@[-$S5<J*!94_\XP2?P&RI^"'IFLW?J.\G:IPI8_P,6^Y.
MY S09N0(:W\%W[F#]:@P18UL@Z.P2=\U]$16UI1EPI)Z2?X"?L==U[A 77)F
ME"""7,Y,WSZ3<%T^9$XGSMC6!5:LH*W= 9ZDCCH=PN1Q+'8'; "X/QE]FJQY
MFJ H#Q-\D@[$8 IB#!UZSICC3$*C/]DJ.2+DAZCJ$):(*]S@WL?Z\Y0I%"J_
M4\FSP[4/3U15 :M6L_LW=DL&% BC#(<I*TB73L9@$$SH#D)%M,6)PA=L6>$+
M/++2!YVB$ZB%^<+(@(7>&J4]@J&U75T%# G[Q>=; LM >QN?,XFJF]"YDLNH
M6",;3QV;LOF\%7/5%EA'X@UC 5TUHI,<2M63V@?!!<@LINAUHM>=8$&D*!9+
MJZ@R+JJ$BO9@791T*C[WHBT4"=$2]F6WZ_!3R.=4 LZL:=M4.8=<"9ERN0U8
M3S%-ATK<A94]$&Q0-;_A'&E>3!H*>5AD6N:+RCU7BG_(:$FQU@Q!=2_>UVP.
MZ*Q>H5$J:51P=D)!.2E0L\\7VNG48@/M'X,QEGM*M%1.MI2C4VT)4L,DD-E!
M1N ;STTY@8M6&^X"12]S!EWQR/ 3Z$.+BG-@U0-?F?1$]V!;..F2@]7LW H!
MAL>*ZL9U6I]5T7'&U?("+-Q)N0X8'9M'<(?+"\,^JU_<X74O+Z/JC]X*[U)8
M4H(@44J6<L[D$13*#+%T[W#>>TM6UPS+'<)P%^[#BDQQ'6I7[=BM4' ,LX]#
M+SD910JO(3::+:]-&2TRS@!.KF[@V3I/<CK.+* 2HLEZGC-%$J"98*8&0T'6
M6GAF^-1)%/3 =A:YLZPLZ[QP+%0<I;7]C$+\7M#_-Z@)M("G)TV)N\$B+5 5
MRD&B4.TR_YM,[$0(67$"<^HQP#T(2V\"C=%RB">.HMUD >DTX[+BM2RJ77O(
M5/HC)GZA>P:M#:8R^VY95L@C22%<I8,DQD8I(LO30V['C^FP4,V#E"!DQM >
MAAIH<REPXD!"M%94HM\,>^0^*1UEP-A:,''D=6+M!#":A06:TBETBUP52\/
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M,HDFB0FS ?;+X\.4G^S()EQ"_I1S,WW4[M^/!0V72N7+G2HDP!+W,X$X8'E
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M4W-U$QU?3@6 -7;!!U,V]X;U38]1O7%>8QUKD&,_]7[L53CZ]=AP_\YEGSG
MI=#CU^,7'N+1Z?75;21*8\,76<_A W%@V?<N=\(;TJE';JD4\MERH9XMEK&$
M+-Y_K/X\,D&%^H:D\%+H!M^N"#8M'18Z]#D6UDO+8(]/V!?7OK>V)H2<1C?
MP?W=XY,^=CXCCB_:_VKR^,@-C4(M6\PWLK5"M;1$&A\@OE#< /5+7F;VX<.'
MA$0NL3/PZ_7)O^#B^>WEQ?'_ U!+ 0(4 Q0    ( +J#9UGW*?OV/@,  #T+
M   1              "  0    !A8VQX+3(P,C0Q,3 W+GAS9%!+ 0(4 Q0
M   ( +J#9UGUL??<6P8  +Y#   5              "  6T#  !A8VQX+3(P
M,C0Q,3 W7VQA8BYX;6Q02P$"% ,4    " "Z@V=9+?H7D;($  !R*@  %0
M            @ '["0  86-L>"TR,#(T,3$P-U]P<F4N>&UL4$L! A0#%
M  @ NH-G6>:BIA[)#@  ?EP   X              ( !X X  &0X-C(T-S-D
M.&LN:'1M4$L! A0#%     @ NH-G63OV.F14)   /N\  !$
M ( !U1T  &0X-C(T-S-D97@Y.3$N:'1M4$L%!@     %  4 0 $  %A"
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d862473d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aclx-20241107.xsd" xlink:type="simple"/>
    <context id="duration_2024-11-07_to_2024-11-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001786205</identifier>
        </entity>
        <period>
            <startDate>2024-11-07</startDate>
            <endDate>2024-11-07</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-238">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-11-07_to_2024-11-07"
      id="Hidden_dei_EntityCentralIndexKey">0001786205</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-249">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-250">2024-11-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-251">Arcellx, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-252">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-253">001-41259</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-254">47-2855917</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-255">800 Bridge Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-256">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-257">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-258">94065</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-259">(240)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-260">327-0630</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-261">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-262">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-263">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-264">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-265">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-266">ACLX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-267">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-11-07_to_2024-11-07" id="ixv-268">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
